CURRENT
ISSUE
1591

Icosapent ethyl (Vascepa – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA for use as an adjunct to maximally tolerated statin therapy to reduce the risk of major adverse cardiovascular events in adults with hypertriglyceridemia (≥150 mg/dL) who have either established cardiovascular disease (CVD) or diabetes and ≥2 additional risk factors for CVD. It is the only omega-3 polyunsaturated fatty acid (PUFA) product to be approved in the US for this indication. Icosapent ethyl and two other omega-3 PUFA prescription products (Lovaza, Epanova), which contain both EPA and docosahexaenoic...  Continue reading

More from Issue 1591
Previous Issue: 1590      January 27, 2020
Coming Soon
Drugs for Depression
Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis
Lasmiditan (Reyvow) for Treatment of Migraine
Palforzia for Treatment of Peanut Allergy
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
 Tweets
FROM
ISSUE
1591

The FDA has approved a progestin-only oral contraceptive ("minipill") containing drospirenone (Slynd – Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone (Camila, and others).1 Progestin-only oral contraceptives are similar in efficacy to combination oral contraceptives.2 They are used predominantly by breastfeeding women and by those in whom estrogen is poorly tolerated or contraindicated. Combination oral contraceptives containing drospirenone ... Continue reading